# Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

> **NCT06916143** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 48 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** LY4100511
- **DRUG:** Rabeprazole

## Key facts

- **NCT ID:** NCT06916143
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-08
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916143, "Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06916143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*